Aegis lifts target on Ampio Pharmaceuticals

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Aegis is out with some upbeat commentary on Ampio Pharmaceuticals (AMPE -1.7%) on the heels of the company's announcement that a subsidiary has struck research agreements with Western Galilee Medical Center and the University of Thessaly where researchers will "utilize Luoxis' proprietary RedoxSYS ORP diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion." (PR)

Additionally, analyst Selvaraju thinks "the company should be able to file for approval [for Ampion] with positive data from a single Phase 3 confirmatory trial."

Price target hiked to $15 from $14.